Loading...

UNITY BIOTECHNOLOGY INC Operational Disruptions 8-K Filing

NTY

UNITY BIOTECHNOLOGY INC

()

2023 8-K

Lease Termination

Company Dissolution

Rights Offerings

Management Changes

Voluntary Delisting

Voluntary Delisting

Management Changes

Q1 Financial Results

Director Resignation

Board Appointment

Financial Results

Management Change

Q3 Financial Results

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Restatement of Financial St...

Earnings Report

Entry into Material Definit...

Announcement of Study Results

Termination of Loan Agreement

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Positive Data Announcement

Departure of Directors or C...

Amendment to Sales Agreement

Financial Results Announcement

Awareness of Bank Closure

External Links:

Unity Biotechnology announced 48-week results from Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD).

AI Assistant

UNITY BIOTECHNOLOGY INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.